News / Health

Ebola Vaccine from GSK Fast-tracked into Clinical Trials

FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building.
FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building.

An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

The research work is being accelerated with funding from an international consortium, reflecting mounting concern over the worst outbreak of the disease that has killed more than 1,500 people in West Africa.

GSK's candidate vaccine, being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from about mid-September, with the program then being extended to Gambia and Mali.

Britain's biggest drugmaker said on Thursday the Phase I trials would start as soon as they received ethical and regulatory approvals.

The NIH's National Institute of Allergy and Infectious Diseases is also working on a wider program of clinical trials, including tests of a version of the GSK vaccine that may fight a second strain of Ebola, as well as the West African one.

In addition, U.S. researchers plan human tests of a vaccine developed by Canadian government scientists, which has been licensed to NewLink Genetics.

The trials being announced will enroll healthy volunteers with the goal of determining whether the vaccine is safe and whether it provokes a protective immune response.

The aim is to complete these tests by the end of 2014, after which vaccines could be deployed on an emergency basis.

Race to test

In a grim assessment of the deadly disease, the World Health Organization said on Thursday that the current Ebola outbreak was continuing to accelerate and could infect more than 20,000 people.

Jeremy Farrar, director of the Wellcome Trust medical charity, which is helping to fund the vaccine trials, said the effectiveness of vaccines and drugs could only be assessed during epidemics, so it was vital to test products now.

GSK plans to begin making up to about 10,000 additional doses of its vaccine at the same time as the initial clinical trials, so if they are successful vaccine could be made available immediately for an emergency immunization program.

NewLink has also contracted for the manufacture of increased supplies of its vaccine.

A steering committee made up of senior officials from NIH and the U.S. Department of Defense also approved last week the first step toward using three advanced laboratories to manufacture Ebola vaccines and treatments, a person familiar with the planning told Reuters.

The three labs, in Texas, Maryland and North Carolina, were set up in 2012 by the U.S. Department of Health and Human Services (HHS) in partnership with private industry to respond to pandemics or chemical, biological, radiological or nuclear threats..

The GSK vaccine consists of a common cold virus, called an adenovirus, that has been engineered to carry two genes of the Ebola virus. Animal testing has shown that when the adenovirus infects cells the Ebola genes produce harmless proteins that stimulate the immune system to produce antibodies to Ebola.

GSK acquired the vaccine after buying Swiss-based biotech company Okairos for 250 million euros ($330 million) last year.

You May Like

Video Getting to Zero AIDS Infections

More than 35 million people around the world are infected with HIV, a disease that is both preventable and treatable

Children, Childhoods Lost in European Refugee Crisis

According to UNICEF, 190,000 children applied for political asylum in Europe in the first 9 months of this year - twice as many as last year

What Happened When I Landed in Antarctica

Refael Klein chronicles what it's like to visit one of the coldest, most desolate places on Earth

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
With HIV, Can We Get to Zero?i
Carol Pearson
November 29, 2015 1:23 PM
The theme of this year's World AIDS Day is "Getting to Zero." The U.N. says new HIV infections have been reduced by 35 percent since 2000 and AIDS-related deaths are down by 42 percent since the peak in 2004. VOA's Carol Pearson takes a look at what it might take to actually have an AIDS-free generation.

Video With HIV, Can We Get to Zero?

The theme of this year's World AIDS Day is "Getting to Zero." The U.N. says new HIV infections have been reduced by 35 percent since 2000 and AIDS-related deaths are down by 42 percent since the peak in 2004. VOA's Carol Pearson takes a look at what it might take to actually have an AIDS-free generation.

Video Political Motives Seen Behind Cancelled Cambodian Water Festival

For the fourth time in the five years since more than 350 people were killed in a stampede at Cambodia’s annual water festival, authorities canceled the event this year. Officials blamed environmental reasons as the cause, but many see it as fallout from rising political tensions with a fresh wave of ruling party intimidation against the opposition. David Boyle and Kimlong Meng report from Phnom Penh.

Video African Circus Gives At-Risk Youth a 2nd Chance

Ethiopia hosted the first African Circus Arts Festival this past weekend with performers from seven different African countries. Most of the performers are youngsters coming form challenging backgrounds who say the circus gave them a second chance.

Video US Lawmakers Brace for End-of-Year Battles

U.S. lawmakers are returning to Washington for Congress’ final working weeks of the year. And, as VOA's Michael Bowman reports, a full slate of legislative business awaits them, from keeping the federal government open to resolving a battle with the White House over the admittance of Syrian refugees.

Video Taiwan Looks for Role in South China Sea Dispute

The Taiwanese government is one of several that claims territory in the hotly contested South China Sea, but Taipei has long been sidelined in the dispute, overshadowed by China. Now, as the Philippines challenges Beijing’s claims in an international court at The Hague, Taipei is looking to publicly assert its claims. VOA’s Bill Ide has more from Beijing.

Video After Terrorist Attacks, Support for Refugees Fades

The terrorists who killed and injured almost 500 people around Paris this month are mostly French or Belgian nationals. But at least two apparently took advantage of Europe’s migrant crisis to sneak into the region. The discovery has hardened views about legitimate refugees, including those fleeing the same extremist violence that hit the French capital. Lisa Bryant has this report for VOA from the Paris suburb of Cergy-Pontoise

Video Syrian Refugees in US Express Concern for Those Left Behind

Syrian immigrants in the United States are concerned about the negative tide of public opinion and the politicians who want to block a U.S. plan to accept 10,000 Syrian refugees. Zlatica Hoke reports many Americans are fighting to dispel suspicions linking refugees to terrorists.

Video Thais Send Security Concerns Down the River

As Thailand takes in the annual Loy Krathong festival, many ponder the country’s future and security. Steve Sandford reports from Chiang Mai.

Video Islamic State Unfazed by Losses in Iraq, Syria

Progress in the U.S.-led effort to beat Islamic State on its home turf in Iraq and Syria has led some to speculate the terror group may be growing desperate. But counterterror officials say that is not the case, and warn the recent spate of terror attacks is merely part of the group’s evolution. VOA National Security correspondent Jeff Seldin has more.

Video Belgium-Germany Border Remains Porous, Even As Manhunt For Paris Attacker Continues

One of the suspected gunmen in the Nov. 13 Paris attacks, Salah Abdeslam, evaded law enforcement, made his way to Belgium, and is now believed to have fled to Germany. VOA correspondent Ayesha Tanzeem makes the journey across the border from Belgium into Germany to see how porous the borders really are.

Video US, Cambodian Navies Pair Up in Gulf of Thailand

The U.S. Navy has deployed one of its newest and most advanced ships to Cambodia to conduct joint training drills in the Gulf of Thailand. Riding hull-to-hull with Cambodian ships, the seamen of the USS Fort Worth are executing joint-training drills that will help build relations in Southeast Asia. David Boyle reports for VOA from Preah Sihanouk province.

Video Uncertain Future for Syrian Refugee Resettlement in Illinois

For the trickle of Syrian refugees finding new homes in the Midwest city of Chicago, the call to end resettlement in many U.S. states is adding another dimension to their long journey fleeing war. Organizations working to help them integrate say the backlash since the Paris attacks is both harming and helping their efforts to provide refugees sanctuary. VOA's Kane Farabaugh reports.

VOA Blogs